Dr Powles speaks to ecancer at ASCO 2025 about an exploratory analysis from the Phase 3 NIAGARA trial examining circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer (MIBC) patients treated with perioperative durvalumab and neoadjuvant chemotherapy.

ctDNA was found to be promising biomarker for treatment response and prognosis in MIBC. Adding durvalumab to chemotherapy improves ctDNA clearance and provides clinical benefit across ctDNA-defined risk groups, supporting its use in the perioperative setting.